P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction: The PRIVATE-ATLANTIC study

Thrombosis and Haemostasis

Volumn 116, Issue 2, 2016, Pages 369-378

  Silvain, Johanne ^a   Storey, Robert F ^b   Cayla, Guillaume ^c   Esteve, Jean Baptiste ^d   Dillinger, Jean Guillaume ^e   Rousseau, Hélène ^e   Tsatsaris, Anne ^f   Baradat, Caroline ^f   Salhi, Néjoua ^f   Hamm, Christian W ^g   Lapostolle, Frédéric ^h   Lassen, Jens Flensted ⁱ   Collet, Jean Philippe ^a   Ten Berg, Jurriën M ^j   Van ‘T Hof, Arnoud W ^k   Montalescot, Gilles ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c DEPARTMENT OF NEUROLOGY   (France)

^d CHU de La Réunion site centre hospitalier Félix Guyon   (France)

^e HÔPITAL LARIBOISIÈRE   (France)

^f ASTRAZENECA   (United Kingdom)

^g KERCKHOFF HEART CENTER   (Germany)

^h AVICENNE HOSPITAL   (France)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^j ST ANTONIUS HOSPITAL   (Netherlands)

^k ISALA HOSPITAL   (Netherlands)

more..

Author keywords

Morphine; PCI; Platelet reactivity; STEMI; Ticagrelor

Indexed keywords

MORPHINE; PLACEBO; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; VASODILATOR STIMULATED PHOSPHOPROTEIN; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY CARE UNIT; CORONARY REPERFUSION; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TANDEM MASS SPECTROMETRY; THROMBOCYTE AGGREGATION INHIBITION; THROMBUS ASPIRATION; ANALOGS AND DERIVATIVES; BLOOD; DRUG ADMINISTRATION; DRUG EFFECTS; MULTIMODALITY CANCER THERAPY; THROMBOCYTE;

ADENOSINE; BLOOD PLATELETS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MORPHINE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; ST ELEVATION MYOCARDIAL INFARCTION;

EID: 84982701461     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-12-0944     Document Type: Article

References (22)

1. Montalescot G, van ‘t Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371: 1016-1027.
2. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopido-grel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-2585.
3. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Car-diol 2013; 61: 1601-1606.
4. Valgimigli M, Tebaldi M, Campo G, et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stent-ing: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Car-diovasc Interv 2012; 5: 268-277.
5. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ti-cagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elev-ation myocardial infarction. Circ Cardiovasc Interv 2012; 5: 797-804.
6. Montalescot G, Lassen JF, Hamm CW, et al. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. Am Heart J 2013; 165: 515-522.
7. Barragan P, Paganelli F, Camoin-Jau L, et al. Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity. Thromb Haemost 2010; 104: 410-411.
8. Abtan J, Silvain J, Kerneis M, et al. Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay. Thromb Haemost 2013; 110: 1055-1064.
9. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109.
10. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010; 66: 487-496.
11. Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010; 56: 1456-1462.
12. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50: 1852-1856.
13. Montalescot G, Borentain M, Payot L, et al. Early vs late administration of gly-coprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. J Am Med Assoc 2004; 292: 362-366.
14. van ‘t Hof AW, ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angio-plasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008; 372: 537-546.
15. ten Berg JM, van ‘t Hof AW, Dill T, et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol 2010; 55: 2446-2455.
16. Hermanides RS, van Werkum JW, Ottervanger JP, et al. The effect of pre-hospi-tal glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI. Catheter Cardiovasc Interv 2012; 79: 956-964.
17. Postma S, Dambrink JH, Ottervanger JP, et al. Early ambulance initiation versus in-hospital initiation of high dose clopidogrel in ST-segment elevation myo-cardial infarction. Thromb Haemost 2014; 112: 606-613.
18. Hobl EL, Stimpfl T, Ebner J, et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2014; 63: 630-635.
19. Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myo-cardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv 2015; 8: pii: e001593.
20. Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ti-cagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2016; 37: 245-252.
21. Hobl EL, Reiter B, Schoergenhofer C, et al. Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers. Eur J Clin Invest 2016; 46: 7-14.
22. Hobl EL, Reiter B, Schoergenhofer C, et al. Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers. Clin Res Cardiol 2015; Epub ahead of print.